DCM Shriram Ltd

- The company has not explicitly mentioned any current or immediate plans for new fundraising through debt or equity in the transcript. - Net debt as of 31st December 2025 stood at Rs 1,084 crores, increased from Rs 867 crores in the previous year, mainly due to capital expenditure and acquisitions. - The company highlighted that major investments in the chemical segment are nearing completion. - With a strong balance sheet and healthy cash flows, the company is well-positioned to explore value-chain opportunities. - The management did not indicate any specific plans for fresh debt or equity issuance but emphasized continuing growth and cash profit generation from existing investments expected to materialize from FY27 onwards.

- The company has invested close to INR 4,000-5,000 crore in the last 3-4 years, primarily in the chemical segment. - The aluminium extrusion project at Kota is on schedule, with phase one slated to be commissioned by the end of the next quarter. - New capacities like Epichlorohydrin (ECH) plant commissioned in October 2025, with remaining balance capacity expected to be commissioned by end of current quarter. - Focus on strengthening value chain and digital transformation to build operational resilience. - Investments are aimed at stabilizing and scaling up businesses, especially chemical verticals like epoxy resins and ECH, which are expected to become profitable by FY '27. - The company is open to exploring further value-chain opportunities aligned with core businesses given their strong balance sheet and cash flows. - No specific mention of new announced capex beyond completion and stabilization of ongoing projects.

- Company expects growth from FY '27 onwards as major chemical segment investments stabilize. - Ongoing efforts to grow value chains across businesses to drive revenue and profit growth. - Caustic soda and chlorine demand outlook stable to positive in coming quarters, despite some large new capacities. - Fenesta business targets around 14% EBITDA margin with expanded capacity and product mix improvements. - Epichlorohydrin plant commissioning nearing completion; expect stable operations and ramp-up post Q4 FY26. - Acquisition of Hindusthan Specialty Chemicals aims for breakeven within 12 months from August 2025. - Bioseed revenues growing, with strong volumes and new product launches. - Sugar production expected to be better than last year; government support on prices and exports could improve margins. - Aluminium extrusion project at Kota on track to be commissioned next quarter. - Digital transformation and operational efficiencies to sustain healthy margins and adaptability.

- The company has invested INR 4,000-5,000 crore over the last 3-4 years, expected to contribute to cash profits from FY '27 onwards. - Earnings and profitability are expected to improve as new investments stabilize and scale up. - The epoxy and Epichlorohydrin businesses are stabilizing; profitability is anticipated from FY '27 with ramp-up in capacity and higher value product focus. - Fenesta business margins are expected to normalize around 14% EBITDA with scale and backward integration benefits. - Sugar segment profitability may remain under pressure currently due to higher costs but is supported by better recoveries and active government policy advocacy. - Overall, the company aims for steady, responsible growth with continuous operational efficiencies and digital transformation driving margin health. - The demerger/spin-off is expected in the next 3-4 months, potentially unlocking further value. - Return on capital employed remained stable at 14%, indicating consistent operational efficiency.

- Fenesta Building Systems saw a slight decline in its order book during the quarter. - The decrease in Fenesta’s order book was attributed partly to product mix shifts and higher fixed costs. - Fenesta’s project vertical led the revenue growth despite the slight order book dip. - No specific figures were provided regarding the current or expected overall order book across all businesses. - The company expects Fenesta margins to stabilize around 14% as scale and backward integration effects come into play. - Other segments like Chemicals and Sugar & Ethanol showed stable or growing demand fundamentals but no explicit order book numbers mentioned. Overall, while Fenesta's order book slightly reduced, the company continues to focus on volume growth and margin improvement; no detailed consolidated order book figures were disclosed.